Los Angeles Capital Management LLC Buys 14,842 Shares of Halozyme Therapeutics, Inc. $HALO

Los Angeles Capital Management LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1.4% during the 4th quarter, Holdings Channel reports. The fund owned 1,095,916 shares of the biopharmaceutical company’s stock after acquiring an additional 14,842 shares during the period. Los Angeles Capital Management LLC’s holdings in Halozyme Therapeutics were worth $70,829,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Measured Wealth Private Client Group LLC lifted its stake in shares of Halozyme Therapeutics by 51.5% in the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares in the last quarter. Larson Financial Group LLC lifted its stake in shares of Halozyme Therapeutics by 3,118.2% in the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 343 shares in the last quarter. Clearstead Advisors LLC lifted its stake in shares of Halozyme Therapeutics by 107.7% in the third quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 265 shares in the last quarter. Harbour Investments Inc. lifted its stake in shares of Halozyme Therapeutics by 152.5% in the fourth quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 372 shares in the last quarter. Finally, Penserra Capital Management LLC bought a new position in shares of Halozyme Therapeutics in the third quarter valued at $52,000. 97.79% of the stock is owned by institutional investors.

Insider Activity

In other news, COO Cortney Caudill sold 8,857 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $67.64, for a total value of $599,087.48. Following the completion of the sale, the chief operating officer owned 7,055 shares in the company, valued at $477,200.20. This represents a 55.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $66.21, for a total transaction of $107,591.25. Following the completion of the sale, the director owned 43,669 shares of the company’s stock, valued at approximately $2,891,324.49. This represents a 3.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 122,107 shares of company stock worth $8,254,834 over the last quarter. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Zacks Research raised Halozyme’s earnings estimates across multiple future periods, including FY2026, FY2027, and FY2028, signaling confidence in the company’s longer-term profit growth. Halozyme Therapeutics article
• Positive Sentiment: Analysts also increased estimates for several individual quarters in 2027, reinforcing a constructive earnings outlook for Halozyme Therapeutics. Halozyme Therapeutics article
• Neutral Sentiment: One near-term forecast was trimmed slightly and another was revised lower, but the overall analyst tone remains mostly favorable. Halozyme Therapeutics article
• Neutral Sentiment: Recent insider selling by the CEO was disclosed, but the trades were executed under a pre-arranged trading plan, which typically lessens investor concern. Halozyme Therapeutics article

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $71.53 on Friday. The firm has a 50-day moving average of $66.79 and a 200-day moving average of $68.74. The company has a market cap of $8.48 billion, a P/E ratio of 25.73, a P/E/G ratio of 0.30 and a beta of 0.88. The company has a debt-to-equity ratio of 8.81, a current ratio of 2.76 and a quick ratio of 2.33. Halozyme Therapeutics, Inc. has a one year low of $51.06 and a one year high of $82.22.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 EPS for the quarter, beating the consensus estimate of $1.54 by $0.06. The company had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.11 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. Equities research analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

HALO has been the topic of a number of recent research reports. UBS Group reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Halozyme Therapeutics in a research note on Wednesday. HC Wainwright raised their price objective on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research note on Wednesday, April 29th. TD Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, May 12th. Finally, Morgan Stanley dropped their price objective on shares of Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Eight investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $81.60.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.